Nahm M H, Olander J V, Magyarlaki M. in healthy infants, toddlers, preschool children, adults, and older adults before and after vaccination with licensed Pn polysaccharide (PS) vaccine (PV) or one of two investigational protein-conjugated Pn vaccines (CV). (This work was presented in part in the 37th Interscience Conference on Antimicrobial Providers and Chemotherapy, October 1997, in Toronto, Ontario, L-Mimosine Canada [13a].) Serum specimens were from 74 subjects enrolled in Pn vaccine immunogenicity studies in the Saint Louis University or college Center for Vaccine Development. Ten toddlers aged 12 to 15 weeks and 10 young adults aged 18 to 39 years received a single dose of licensed 23-valent Pn PV (Pneumovax-23; Merck & Co.) (PV1). Ten babies aged 6 to 10 weeks, 10 children aged 2 to 5 years, and 10 young adults aged 18 to 39 years received an investigational seven-valent Pn PS conjugated to the outer membrane protein of (Pn-OMP; Merck & Co.) (CV1). Babies in L-Mimosine the CV1 vaccine group received a total of three doses of vaccine at 2, 4, and 6 months of age, and children aged 2 to 5 years received two doses of vaccine given 2 months apart. All other subjects received a single dose of vaccine. Twelve older adults aged 50 to 85 years received a licensed 23-valent Pn PV (Pnu-Imune; Wyeth-Lederle and Pediatrics, Pearl River, N.J.) (PV2), and 12 older adults aged 50 to 85 years received an investigational five-valent Pn PS conjugated to the carrier protein CRM197, Mouse monoclonal to KID a nontoxic variant of diphtheria toxin (5VPn-CRM; Wyeth-Lederle and Pediatrics) (CV2). The licensed Pn PVs were comprised of 25 g of purified PS of each of the same 23 capsular PSs per dose. The 7VPn-OMP vaccine contained 3.5 g of type 6B PS, 2 g of type 19F PS, 1.5 g of type 9V PS, and 1 g each of type 4, 14, 18C, and 23F PSs per dose. The 5VPn-CRM vaccine contained 10 g of PS each for Pn serotypes 6B, L-Mimosine 14, 18C, 19F, and 23F per dose. Prevaccination specimens were from all subjects. Postvaccination specimens for babies and children receiving CV1 were acquired one month following administration of the final dose. For all other subjects, the postvaccination specimens were acquired one month postadministration of a single dose of CV or PV. Relative concentrations of IgG1 and IgG2 antibodies to Pn serotypes 6B, 14, 18C, 19F, and 23F were determined by enzyme-linked immunosorbent assay (ELISA) inside a cross-calibration adaptation of previously explained Pn ELISA consensus methods (6, 7, 13). The U.S. standard human being anti-type b (Hib) serum pool, lot 1983 (provided by Carl Frasch; Center for Biologics Evaluation and Review, Food and Drug Administration, Rockville, Md.), having defined concentrations of IgG subclass antibodies to Hib antigen (30.9 g of IgG1 per ml and 16.1 g of IgG2 per ml), was used like a research serum. The assay was adapted as follows. Ninety-six-well Maxisorp microtiter plates (Nunc-Bacti; Fisher Scientific, St. Louis, Mo.) were coated with Hib L-Mimosine oligosaccharide antigen conjugated to human being serum albumin (HbO-HA; provided by Porter Anderson, University or college of Rochester, Rochester, N.Y.) at 2 g/ml within the calibration part of the plate. The test sides of the plates were coated with type-specific Pn PS (American Type Tradition Collection Manassas, Va.) at a covering concentration of 20 g/ml. Study sera were preabsorbed with 10 g of C-PS (C polysaccharide, the common antigen of 0.05) (Fig. ?(Fig.1).1). Even though IgG concentrations were low, IgG subclass ratios of naturally acquired antibodies recognized in prevaccination specimens showed trends between age groups that paralleled those of postvaccination specimens. Babies who received 7VPn-OMP were more likely to demonstrate a twofold-or-greater increase in IgG1 subclass antibodies to Pn serotypes 6B, 14, 19F, and 23F than toddlers who received unconjugated Pn PV (80 to 100% versus 10 to 20%, 0.01). The effect of enhanced immunogenicity of a protein-conjugate vaccine in babies was expected given previous immunogenicity studies (16). Enhanced immunogenicity was not seen in the young-adult group given the 7VPn-OMP vaccine, nor was it seen in the older-adult.